CanSino Biologic, a company based in Tianjin, China working with a clinical team in Wuhan, report the results of a phase 1 safety trial of an adenovirus vector based SARS-CoV-2 vaccine candidate. The virus vector expressed the entire spike protein, the S gene.
Three groups of healthy volunteers, 36 per group, were administered three escalating doses of the vaccine by intramuscular injection. The volunteers were young, average age 36 (ages-18-60, only 17 of the 108 volunteers were ages 50-60) half male, half female. The vaccinated volunteers were followed for 28 days post inoculation. The primary endpoints were adverse reactions on day 7 and safety at day 28. Immunologic parameters were also assessed.
No serious side effects were noted throughout he study period. Common side effects observed at all doses included muscle pain at the site of injection, headache, fatigue and fever—all transient.
Originally posted on Forbes (May 22, 2020)